A PILOT FEASIBILITY STUDY OF INTRACEREBRAL MICRODIALYSIS TO DETERMINE THE NEURO

脑内微透析确定神经元的试点可行性研究

• 批准号: 7716657
• 负责人: JANA PORTNOW
• 金额: $ 2.16万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-20 至 2008-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7716657
• 关键词: Anesthesia procedures; Biopsy; Brain Neoplasms; Catheters; Cerebral cortex; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Craniotomy; Dose; Feasibility Studies; Funding; Goals; Grant; Institution; Microdialysis; New Agents; Patients; Pharmaceutical Preparations; Phase; Plasma; Protocols documentation; Research; Research Personnel; Resources; Screening procedure; Source; System; Tumor Debulking; United States National Institutes of Health; chemotherapy; temozolomide; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The overall goal of this protocol is to develop a system for efficiently screening new agents for potential use in Phase I and II brain tumor clinical trials by directly determining if these drugs can cross the BBB in patients with brain tumors. The plan is to place a microdialysis catheter into either the tumor or adjacent cerebral cortex when a brain tumor patient undergoes a biopsy or debulking craniotomy. Once the patient has recovered from the anesthesia and is stable post-operatively, s/he will be given a dose of a systemic chemotherapy agent (in this feasibility study temozolomide, a drug already known to cross the BBB, will be used), and intracerebral microdialysis will be performed to determine if any of the drug is recovered in the dialysate, reflecting the degree to which the drug is able to penetrate the BBB. Drug levels in the brain tumor interstitium will be compared to levels in the plasma.

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 该方案的总体目标是开发一种系统，通过直接确定这些药物是否可以穿过脑肿瘤患者的BBB，有效筛选可能用于I期和II期脑肿瘤临床试验的新药。该计划是在脑瘤患者接受活检或开颅手术时，将微透析导管置入肿瘤或邻近的大脑皮层。一旦患者从麻醉中恢复并在术后稳定，将给予她/他一剂全身化疗药物（在本可行性研究中，将使用已知可以穿过BBB的药物替莫唑胺），并进行脑内微透析以确定是否有任何药物在透析液中回收，反映药物能够穿透BBB的程度。将脑肿瘤组织中的药物水平与血浆中的水平进行比较。